IRIS

trans-1,2-Dichloroethylene

CASRN 156-60-5 | DTXSID7024031

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (22 pp, 215 K) Last Updated: 09/30/2010

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Immune 2 x 10 -2 Decrease in number of antibody forming cells (AFCs) against sheep red blood cells (sRBCs) in male mice BMDL 1SD : 65.0
mg/kg-day
3000 Low

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (22 pp, 215 K) Last Updated: 09/30/2010
Information reviewed but value not estimated.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (22 pp, 215 K) Last Updated: 09/30/2010

WOE Characterization Framework for WOE Characterization
Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of trans-1,2-DCE.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (22 pp, 215 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (22 pp, 215 K)

Not assessed under the IRIS Program.

Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.

Contact Us to ask a question, provide feedback or report a problem.